Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 AntibodyJames J. Harding(Memorial Sloan Kettering Cancer Center)Clinical Cancer ResearchJanuary 29, 202110.1158/1078-0432.ccr-20-4405Cited by 157SaveCiteExport RISWatch citationsRelated PapersSupplementary data1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors|Unknown|2025|0